170 related articles for article (PubMed ID: 21317595)
1. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
[TBL] [Abstract][Full Text] [Related]
2. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
[TBL] [Abstract][Full Text] [Related]
3. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
[TBL] [Abstract][Full Text] [Related]
5. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
[TBL] [Abstract][Full Text] [Related]
6. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
[TBL] [Abstract][Full Text] [Related]
7. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
8. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
[TBL] [Abstract][Full Text] [Related]
9. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
Friedland G; Vlahov D
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
[No Abstract] [Full Text] [Related]
10. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
[TBL] [Abstract][Full Text] [Related]
11. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
Korthuis PT; Tozzi MJ; Nandi V; Fiellin DA; Weiss L; Egan JE; Botsko M; Acosta A; Gourevitch MN; Hersh D; Hsu J; Boverman J; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S39-45. PubMed ID: 21317593
[TBL] [Abstract][Full Text] [Related]
12. A trial of integrated buprenorphine/naloxone and HIV clinical care.
Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
[TBL] [Abstract][Full Text] [Related]
13. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.
Baker JR; Best AM; Pade PA; McCance-Katz EF
Ann Pharmacother; 2006 Mar; 40(3):392-6. PubMed ID: 16507617
[TBL] [Abstract][Full Text] [Related]
14. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
15. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
[TBL] [Abstract][Full Text] [Related]
16. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
[TBL] [Abstract][Full Text] [Related]
17. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
[TBL] [Abstract][Full Text] [Related]
18. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
[TBL] [Abstract][Full Text] [Related]
19. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
Weiss L; Egan JE; Botsko M; Netherland J; Fiellin DA; Finkelstein R
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S7-13. PubMed ID: 21317598
[TBL] [Abstract][Full Text] [Related]
20. HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment.
Edelman EJ; Moore BA; Caffrey S; Sikkema KJ; Jones ES; Schottenfeld RS; Fiellin DA; Fiellin LE
J Addict Med; 2013; 7(6):410-6. PubMed ID: 24189173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
